Alexandria Stops Waiting for Biotech and Starts Paying for the Pivot
A $638 million impairment, a REIT-first junior subordinated note, and a quiet reversal on owning more of its megacampuses — ARE's story has moved from science to capital structure.
ARE · Earnings Call · 2026-10-27
The bill finally arrives
For five straight quarters, Alexandria Real Estate's calls followed a ritual: concede that the life science winter is real, insist the bottom is close, and promise that leasing is about to inflect. The Q3 2026 call broke the ritual — not by finding the bottom, but by refusing to keep waiting for it. The company booked $638 million of real estate impairments, shrank its development pipeline by more than half in a year (3.6 million square feet down to 1.6 million), and re-anchored the whole narrative on one number: non-income-producing assets as a share of gross assets, down from 20% at the end of 2024 to 12%.
We did recognize impairments of real estate of $638 million during the quarter, of which substantially all of this amount is related to developments in process, land, or properties that were laboratory conversion opportunities.
The two biggest marks tell you exactly where the dream died: 421 Park Drive in the Fenway — an under-construction lab acquired in January 2021, now under contract to an institutional user who will absorb roughly $136 million of interior lab build-out — and a four-building Palo Alto office project bought in 2022 to convert to labs, in a submarket that simply never delivered the life science demand. This is management marking its own 2021-22 underwriting to market, in public.
The tape has already voted. ARE is down 19.5% over the last 90 trading days and 27.5% from its September 17 peak of $56.34, and sits 81.7% below its 2021 high. A company that had spent a decade being valued as the landlord to the biology revolution is now being valued as a de-levering story.
Capital structure is the new leasing
What management is adding is just as telling as what it is writing off. The headline capital event was a $1 billion junior subordinated notes offering at 7.25% — which Marcus flagged as a first-of-its-kind REIT debut for the instrument, and which the rating agencies award 50% equity credit. Sandwiched around it: a $475 million joint venture at Campus Point, where ARE keeps control and consolidation, pays its partner a 5.5% minimum, holds a call, and grants a put exercisable after seven years; and $2.6 billion of completed plus pending dispositions and partial interest sales, roughly $720 million above the $1.9 billion midpoint, giving them room to slide proceeds into 2027.
That is a company arbitraging its own cost of capital rather than waiting for the lab leasing market to heal. And it is a reversal worth naming. Through the October 2025 call, the message was the opposite:
“I don't think that is our game plan because I think over time, our goal is actually to own more of the Megacampus rather than less.” — Joel Marcus, Executive Chairman · 2025-10-28
Twelve months later, a partial interest in a megacampus has been sold, and management is openly describing a second, multi-asset JV that mixes core and non-core. The keyword table says the same thing: joint venture and partial interest sales now sit at the very top of the company's language, while words like disposition program and buyer pool faded. Also dropped, sharply, was the science voice — the tenant-health and biology commentary that used to carry these calls is largely absent from this one, and the word "Hallie" registers as the quarter's single biggest language decliner. That is what it looks like when a REIT's earnings call is handed from the research bench to the treasurer.
The note is not free money, and Peter Moglia was blunt when an analyst used the word "guaranteed":
“There is no guarantee, just to be clear. You had stated that it was guaranteed. That is not true.” — Peter M. Moglia, Chief Executive Officer and Chief Investment Officer · 2026-10-27
The carrying cost shows up below the FFO line, not above it: liabilities to assets reached 44.6%, up 2.4pp year over year, which is why the 5.6x-6.2x year-end leverage target, and a "mid-5" intermediate goal, now anchors every sentence about capital.
Advanced technology is the escape hatch — and it is already crowded
The operating story that genuinely improved: 1.24 million square feet leased, the best volume in seven quarters, including 451,000 square feet of previously vacant space — the second-largest such quarter in company history. Leases aggregating 1.3 million square feet will add 3.7% to occupancy, but they don't commence until June 2027 on average. Occupancy was 87.1%, up just 20 basis points, and same-property NOI fell 6.7% (2.8% cash).
The strategic answer to a lab market with too much supply is to re-tenant that supply to someone else. Advanced technology tenants — a phrase that first spiked to the top of ARE's own keyword list in mid-2026 — are now the explicit plan at 311 Arsenal (cutting future construction needs by about $220 million), 40 Sylvan and 3000 Minuteman.
“It is also going to take a lot of the current supply that was built as or marketed as lab, but probably shouldn't have been.” — Peter M. Moglia, Chief Executive Officer and Chief Investment Officer · 2026-10-27
It is a sensible trade: lower rent, materially lower capex, faster cash. But note the destination is cooling. The market's AI data center complex — the demand pool ARE is implicitly pointing at — de-rated hard over the last 30 days, with the great majority of the tickers in that basket falling. Pivoting a life science portfolio toward compute-adjacent tenants a year into that trade's drawdown is not obviously a safety net; it may just be chasing the last cycle's winner.
The part that got quieter
Three language shifts deserve attention. First, cap rates: in January 2026 Peter Moglia said “we do think our top end properties should have a 5 handle” — Peter M. Moglia, Co-Chief Executive Officer · 2026-01-27. This quarter the same executive offered a materially wider grid — Campus Point still near 5%, but “our better assets would trade with a 6 cap handle on it” — Peter M. Moglia, Chief Executive Officer and Chief Investment Officer · 2026-10-27, with workhorse assets at 7.5-8.5. That is a repricing of the core, not the fringe, and it is the kind of admission that feeds directly into NAV debates.
Second, free rent concession language, once the loudest theme of the 2025-26 calls, has lost its urgency — now framed as "elevated" at two months per year of term, and 1.1 months ex-one large non-life-science lease in Research Triangle.
Third, the tenant-demand datapoint that management rode for two quarters has rolled over: tenants in market rose ~30% sequentially in Q1, another ~10% in Q2, and fell 5% this quarter. Public biotech was just 1.1% of leasing volume. And the near-term occupancy path is explicitly negative: “we expect temporary pressure on occupancy in the first half of 2027” — Marc E. Binda, Chief Financial Officer and Treasurer · 2026-10-27, driven by 1.4 million square feet of lease expirations with 9-24 months of downtime against $101 million of expiring rent, with occupancy growth only returning in 2028.
The bottom line
Alexandria is no longer arguing that the worst is behind it; it is financing its way through the worst. The FFO guide of $6.40 ± $0.02 is intact, cash generation is still real ($337 million of operating cash flow in the latest reported quarter), and the sales pipeline is genuinely ahead of target. But earnings quality is deteriorating: net income of -$74 million in the last reported quarter sits against a price-to-earnings multiple near 99x. Note that these fundamentals predate the Q3 impairment entirely.
The company that spent a decade telling investors it would own more of its best campuses has started selling pieces of them, and the company that sold investors on the science has started selling them on the coupon. That can be the right call. It is unambiguously a different company than the one that reported a year ago — and the market, down 19.5% in three months, is still deciding whether to pay for the transition or for what is being left behind.